| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by investing activities | 750 | 750 |
| Proceeds from espp purchases | 6 | 5 |
| Net cash provided by financing activities | 6 | 5 |
| Net decrease in cash and cash equivalents | -3,122 | -2,866 |
| Cash and cash equivalents at beginning of period | 4,242 | - |
| Cash and cash equivalents at end of period | 1,120 | - |
Arcadia Biosciences, Inc. (RKDA)
Arcadia Biosciences, Inc. (RKDA)